Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip.
Mekonos has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in November 2021.
Mekonos's investors include TDK Ventures, Sands Capital Ventures, Novartis, Creative Destruction Lab, S32.
Mekonos is headquartered in Alameda, United States.
Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip.
Mekonos is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mekonos — Funding & Investors." VCBacked, November 9, 2021, https://www.vcbacked.co/company/mekonos. Accessed October 1, 2026.
VCBacked. (2021). Mekonos — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/mekonos
{{cite web |title=Mekonos — Funding & Investors |url=https://www.vcbacked.co/company/mekonos |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated